228 related articles for article (PubMed ID: 31875696)
1. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-García P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
2. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies targeting the ubiquitin proteasome system in cancer.
Weathington NM; Mallampalli RK
J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
[TBL] [Abstract][Full Text] [Related]
4. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Kambhampati S; Wiita AP
Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.
Auner HW; Cenci S
Br J Haematol; 2015 Jan; 168(1):14-25. PubMed ID: 25296649
[TBL] [Abstract][Full Text] [Related]
6. Enhancing ER stress in myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Jul; 9(7):1645-1646. PubMed ID: 28758893
[No Abstract] [Full Text] [Related]
7. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
8. Role of the ubiquitin-proteasome system and autophagy in regulation of insulin sensitivity in serum-starved 3T3-L1 adipocytes.
Zhang Y; Ye M; Chen LJ; Li M; Tang Z; Wang C
Endocr J; 2015; 62(8):673-86. PubMed ID: 25959705
[TBL] [Abstract][Full Text] [Related]
9. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
10. Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors.
Zhou X; He R; Hu WX; Luo S; Hu J
Neoplasia; 2024 Apr; 50():100974. PubMed ID: 38364355
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
12. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
13. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
14. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
15. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC; Fink EE; Nikiforov MA
Pharmacol Res; 2016 Mar; 105():210-5. PubMed ID: 26827824
[TBL] [Abstract][Full Text] [Related]
19. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Hideshima T; Anderson KC
Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
Li X; Zhu F; Jiang J; Sun C; Zhong Q; Shen M; Wang X; Tian R; Shi C; Xu M; Peng F; Guo X; Hu J; Ye D; Wang M; Qin R
Autophagy; 2016 Sep; 12(9):1521-37. PubMed ID: 27308733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]